Ocata Therapeutics Inc fka OCAT

[Spetty772002]

Fordwill, I would have to disagree with you to some extent. I can point out several examples of companies whose share price skyrocketed long before they were ever approved based on strong Phase II clinical trial results. HGSI, NBIX, VRTX to name a few. Even EXEL recently has had a market cap of over $1 billion a couple different times over the past few years, and as far as I know, they've never even had an FDA review.

I think it depends on the nature of the company we're talking about. Given how novel ACTC's technology is and the revenue potential in the Dry AMD market alone (not to mention any of the other treatments they're working on), I think we could see a large share price increase well before the FDA ever reviews it, however, like DNDN, since it will will likely be the first HESC company to be reviewed for final approval by the FDA, it will probably face great scrutiny and may take more than one try to get passed by the FDA.